Češka - češčina - SUKL (Státní ústav pro kontrolu léčiv)

pfizer, spol. s r.o., praha array - 8280 gestoden; 578 ethinylestradiol - potahovaná tableta - 0,060mg/0,015mg - gestoden a ethinylestradiol

Češka - češčina - SUKL (Státní ústav pro kontrolu léčiv)

gedeon richter plc., budapešť array - 19413 mikronizovanÝ dienogest; 19414 mikronizovanÝ ethinylestradiol - potahovaná tableta - 2mg/0,03mg - dienogest a ethinylestradiol

Češka - češčina - SUKL (Státní ústav pro kontrolu léčiv)

medochemie ltd., limassol array - 19105 dapoxetin-hydrochlorid - potahovaná tableta - 30mg - dapoxetin

Češka - češčina - SUKL (Státní ústav pro kontrolu léčiv)

medochemie ltd., limassol array - 19105 dapoxetin-hydrochlorid - potahovaná tableta - 60mg - dapoxetin

Češka - češčina - SUKL (Státní ústav pro kontrolu léčiv)

berlin-chemie ag, berlín array - 19105 dapoxetin-hydrochlorid - potahovaná tableta - 30mg - dapoxetin

Češka - češčina - SUKL (Státní ústav pro kontrolu léčiv)

berlin-chemie ag, berlín array - 19105 dapoxetin-hydrochlorid - potahovaná tableta - 60mg - dapoxetin

Češka - češčina - SUKL (Státní ústav pro kontrolu léčiv)

gedeon richter plc., budapešť array - 578 ethinylestradiol; 461 levonorgestrel; 578 ethinylestradiol; 461 levonorgestrel; 578 ethinylestradiol; 461 levonorgestrel - obalená tableta - levonorgestrel a ethinylestradiol

Češka - češčina - SUKL (Státní ústav pro kontrolu léčiv)

gedeon richter plc., budapešť array - 8280 gestoden; 578 ethinylestradiol - potahovaná tableta - 60mcg/15mcg - gestoden a ethinylestradiol

Češka - češčina - SUKL (Státní ústav pro kontrolu léčiv)

aristo pharma gmbh, berlin array - 11275 drospirenon; 578 ethinylestradiol - potahovaná tableta - 3mg/0,02mg - drospirenon a ethinylestradiol

Evropska unija - češčina - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - ipilimumab - melanoma; carcinoma, renal cell; carcinoma, non-small-cell lung; mesothelioma, malignant; colorectal neoplasms - antineoplastická činidla - melanomayervoy as monotherapy or combination with nivolumab is indicated for the treatment of advanced (unresectable or metastatic) melanoma in adults and adolescents 12 years of age and older (see section 4.  yervoy in combination with nivolumab is indicated for the treatment of advanced (unresectable or metastatic) melanoma in adults. relative to nivolumab monotherapy, an increase in progression-free survival (pfs) and overall survival (os) for the combination of nivolumab with ipilimumab is established only in patients with low tumour pd-l1 expression (see sections 4. 4 a 5. renal cell carcinoma (rcc)yervoy in combination with nivolumab is indicated for the first-line treatment of adult patients with intermediate/poor-risk advanced renal cell carcinoma (see section 5. non-small cell lung cancer (nsclc)yervoy in combination with nivolumab and 2 cycles of platinum-based chemotherapy is indicated for the first-line treatment of metastatic non-small cell lung cancer in adults whose tumours have no sensitising egfr mutation or alk translocation. malignant pleural mesothelioma (mpm)yervoy in combination with nivolumab is indicated for the first-line treatment of adult patients with unresectable malignant pleural mesothelioma. mismatch repair deficient (dmmr) or microsatellite instability-high (msi-h) colorectal cancer (crc)yervoy in combination with nivolumab is indicated for the treatment of adult patients with mismatch repair deficient or microsatellite instability-high metastatic colorectal cancer after prior fluoropyrimidine based combination chemotherapy (see section 5. oesophageal squamous cell carcinoma (oscc)yervoy in combination with nivolumab is indicated for the first-line treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma with tumour cell pd-l1 expression ≥ 1%.